Our First Radiogenomics Assay — PROSTOX
The PROSTOX test helps prostate cancer patients avoid toxicity from radiation therapy.
Our first microRNA-based radiogenomics assay is for prostate cancer patients who are being offered stereotactic body radiation therapy (SBRT).
The PROSTOX test analyzes the patient's germline DNA to determine if the individual is at increased risk of late grade ≥2 genitourinary (GU) toxicity following radiation therapy.
PROSTOX reports the risk of late GU radiation toxicity based on their mirSNP signature. The assay provides a risk score (low or high) that may be useful to help identify the safest course of treatment to avoid toxicity in the management of their prostate cancer.
To learn more about PROSTOX:
Publications-Radiogenomics and Prostate Cancer
- Kishan AU, et al. Long-term outcomes of stereotactic body radiotherapy for low-risk and intermediate-risk prostate cancer. JAMA Network Open 2019;2:e188006.
- Weidhaas, JB, et al. MicroRNA-based biomarkers of the radiation response in prostate cancer. Journal of Clinical Oncology 38, no. 6_suppl (February 20, 2020) 163-163. DOI: 10.1200/JCO.2020.38.6_suppl.163.
- Kishan AU, et al. Germline variants disrupting microRNAs predict long-term genitourinary toxicity after prostate cancer radiation. Journal for Radiotherapy and Oncology 2022;167:226-232. doi: 10.1016/j.radonc.2021.12.040.